A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.10327-10328 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10328 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 10327 |
| container_title | Blood |
| container_volume | 140 |
| creator | Juckett, Mark Mailankody, Sham Eghtedar, Alireza Bickers, Cara Zong, Xingyue Wong, Lilly Ly, Thomas Byon, John Cooley, Sarah Valamehr, Bahram Chu, Yu-Waye Vij, Ravi |
| description | |
| doi_str_mv | 10.1182/blood-2022-166728 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_166728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122062000</els_id><sourcerecordid>S0006497122062000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1858-8bc567988b10d2afc133bb54822917eed00a52549b88f037d8c9aa3e4516109d3</originalsourceid><addsrcrecordid>eNp9kM1O3DAUha2KSgy0D8DuPsAYbCdOHHWFArSo_ImZriPHvm6MnHjkZKB5oz5mGaZiyeoujr5zrj5CTjg75VyJszbEaKlgQlBeFKVQn8iCS6EoY4IdkAVjrKB5VfJDcjSOT4zxPBNyQf6ew0OnR4RrWE1bO0N0cLWWmVqCHuDeOTp1SFcdBreE222Y_CbgH7T0cvjtB8SEdgn-YVXTC0z-GS3c_YQaQ4B1h0lvZvAD1LFv_aAnHwd48VMHFzrpadtve93u8kcMejOiPXtEl7SZYprft-B2xhB7_YV8djqM-PX_PSa_ri7X9Q96c__9uj6_oYYrqahqjSzKSqmWMyu0MzzL2lbmSoiKl4iWMS2FzKtWKcey0ipTaZ1hLnnBWWWzY8L3vSbFcUzomk3yvU5zw1mzU928qW52qpu96lfm257B18eePaZmNB4Hg9YnNFNjo_-A_gf10IbD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Juckett, Mark ; Mailankody, Sham ; Eghtedar, Alireza ; Bickers, Cara ; Zong, Xingyue ; Wong, Lilly ; Ly, Thomas ; Byon, John ; Cooley, Sarah ; Valamehr, Bahram ; Chu, Yu-Waye ; Vij, Ravi</creator><creatorcontrib>Juckett, Mark ; Mailankody, Sham ; Eghtedar, Alireza ; Bickers, Cara ; Zong, Xingyue ; Wong, Lilly ; Ly, Thomas ; Byon, John ; Cooley, Sarah ; Valamehr, Bahram ; Chu, Yu-Waye ; Vij, Ravi</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-166728</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.10327-10328</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1858-8bc567988b10d2afc133bb54822917eed00a52549b88f037d8c9aa3e4516109d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Juckett, Mark</creatorcontrib><creatorcontrib>Mailankody, Sham</creatorcontrib><creatorcontrib>Eghtedar, Alireza</creatorcontrib><creatorcontrib>Bickers, Cara</creatorcontrib><creatorcontrib>Zong, Xingyue</creatorcontrib><creatorcontrib>Wong, Lilly</creatorcontrib><creatorcontrib>Ly, Thomas</creatorcontrib><creatorcontrib>Byon, John</creatorcontrib><creatorcontrib>Cooley, Sarah</creatorcontrib><creatorcontrib>Valamehr, Bahram</creatorcontrib><creatorcontrib>Chu, Yu-Waye</creatorcontrib><creatorcontrib>Vij, Ravi</creatorcontrib><title>A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kM1O3DAUha2KSgy0D8DuPsAYbCdOHHWFArSo_ImZriPHvm6MnHjkZKB5oz5mGaZiyeoujr5zrj5CTjg75VyJszbEaKlgQlBeFKVQn8iCS6EoY4IdkAVjrKB5VfJDcjSOT4zxPBNyQf6ew0OnR4RrWE1bO0N0cLWWmVqCHuDeOTp1SFcdBreE222Y_CbgH7T0cvjtB8SEdgn-YVXTC0z-GS3c_YQaQ4B1h0lvZvAD1LFv_aAnHwd48VMHFzrpadtve93u8kcMejOiPXtEl7SZYprft-B2xhB7_YV8djqM-PX_PSa_ri7X9Q96c__9uj6_oYYrqahqjSzKSqmWMyu0MzzL2lbmSoiKl4iWMS2FzKtWKcey0ipTaZ1hLnnBWWWzY8L3vSbFcUzomk3yvU5zw1mzU928qW52qpu96lfm257B18eePaZmNB4Hg9YnNFNjo_-A_gf10IbD</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Juckett, Mark</creator><creator>Mailankody, Sham</creator><creator>Eghtedar, Alireza</creator><creator>Bickers, Cara</creator><creator>Zong, Xingyue</creator><creator>Wong, Lilly</creator><creator>Ly, Thomas</creator><creator>Byon, John</creator><creator>Cooley, Sarah</creator><creator>Valamehr, Bahram</creator><creator>Chu, Yu-Waye</creator><creator>Vij, Ravi</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma</title><author>Juckett, Mark ; Mailankody, Sham ; Eghtedar, Alireza ; Bickers, Cara ; Zong, Xingyue ; Wong, Lilly ; Ly, Thomas ; Byon, John ; Cooley, Sarah ; Valamehr, Bahram ; Chu, Yu-Waye ; Vij, Ravi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1858-8bc567988b10d2afc133bb54822917eed00a52549b88f037d8c9aa3e4516109d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Juckett, Mark</creatorcontrib><creatorcontrib>Mailankody, Sham</creatorcontrib><creatorcontrib>Eghtedar, Alireza</creatorcontrib><creatorcontrib>Bickers, Cara</creatorcontrib><creatorcontrib>Zong, Xingyue</creatorcontrib><creatorcontrib>Wong, Lilly</creatorcontrib><creatorcontrib>Ly, Thomas</creatorcontrib><creatorcontrib>Byon, John</creatorcontrib><creatorcontrib>Cooley, Sarah</creatorcontrib><creatorcontrib>Valamehr, Bahram</creatorcontrib><creatorcontrib>Chu, Yu-Waye</creatorcontrib><creatorcontrib>Vij, Ravi</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Juckett, Mark</au><au>Mailankody, Sham</au><au>Eghtedar, Alireza</au><au>Bickers, Cara</au><au>Zong, Xingyue</au><au>Wong, Lilly</au><au>Ly, Thomas</au><au>Byon, John</au><au>Cooley, Sarah</au><au>Valamehr, Bahram</au><au>Chu, Yu-Waye</au><au>Vij, Ravi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>10327</spage><epage>10328</epage><pages>10327-10328</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-166728</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.10327-10328 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_166728 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A35%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%20I%20Study%20of%20FT538,%20an%20Off-the-Shelf,%20Multiplexed-Engineered,%20iPSC-Derived%20NK%20Cell%20Therapy%20in%20Combination%20with%20Daratumumab%20in%20Relapsed/Refractory%20Multiple%20Myeloma&rft.jtitle=Blood&rft.au=Juckett,%20Mark&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=10327&rft.epage=10328&rft.pages=10327-10328&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-166728&rft_dat=%3Celsevier_cross%3ES0006497122062000%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122062000&rfr_iscdi=true |